(Q37747986)

22 August 2017

0 references

1 reference

title

A systematic review and meta-analysis on the therapeutic equivalence of statins (English)

1 reference

22 August 2017

0 references

1 reference

T-C Weng

1

1 reference

22 August 2017

Y-H Kao Yang

series ordinal

2

1 reference

22 August 2017

S-J Lin

series ordinal

3

1 reference

22 August 2017

S-H Tai

series ordinal

4

1 reference

22 August 2017

1 April 2010

1 reference

Journal of Clinical Pharmacy and Therapeutics

22 August 2017

1 reference

22 August 2017

35

1 reference

22 August 2017

2

1 reference

22 August 2017

139-151

1 reference

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

22 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Current methods of the US Preventive Services Task Force: a review of the process

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Statin safety: lessons from new drug applications for marketed statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Hemostatic effects of atorvastatin versus simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

A comparative study of atorvastatin and simvastatin as monotherapy for mixed hyperlipidaemia in Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Meeting national cholesterol education goals in clinical practice--a comparison of lovastatin and fluvastatin in primary prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. The Quality of Life Multicenter Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Achieving lipid goals in real life: the Dutch DISCOVERY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01085.X

10.1111/J.1365-2710.2009.01085.X

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference